Phase 1 Study of Novel Anti-platelet Agent to Overcome Pharmacogenomic Limitations of Clopidogrel

Overview

Journal Open Heart

Publisher BMJ Publishing Group

Specialty Cardiology & Vascular Diseases

Date 2025 Feb 11

PMID 39933830

Authors

Anil Pareek

Nitin Chandurkar

Vivek Raut

Kumar Naidu

Affiliations

Soon will be listed here.

Abstract

Aims: Clopidogrel is the most commonly prescribed thienopyridine as part of dual anti-platelet therapy for the treatment of cardiovascular diseases. However, clopidogrel responsiveness shows variability based on CYP2C19 polymorphism. Therefore, we planned a study with an objective of evaluating safety, tolerability, pharmacodynamics and pharmacokinetics of a novel thienopyridine antiplatelet agent AT-10 in healthy Indian subjects compared with standard dosage regimen of clopidogrel based on their CYP2C19 genotyping.

Methods: Two CYP2C19 genotype-based groups were identified, that is, poor metabolisers and extensive metabolisers, with 20 subjects in each group (n=40) for participating in a randomised, two-period, crossover study. Each study period lasted 6 days including administration of loading and maintenance doses of AT-10 (40 mg/10 mg) or clopidogrel (300 mg/75 mg). The pharmacokinetics and pharmacodynamics were assessed on day 1 and day 6 at several time intervals.

Results: Overall result of pharmacodynamic parameters showed that mean %inhibition of platelet aggregation between AT-10 and clopidogrel in all subjects at 6 hours postdose (loading dose) (AT-10: clopidogrel; 73.30% vs 18.53%) and 6 hours postdose on day 6 (maintenance dose) (AT-10: clopidogrel; 83.41% vs 51.19 %) obtained from the AT-10 group was significantly higher than the clopidogrel group. Further, %inhibition of platelet aggregation from AT-10 treatment in poor metaboliser group was significantly higher than the clopidogrel treatments in extensive metaboliser group.Overall pharmacokinetic comparison in all subjects indicates that AT-10 gives greater exposure to active Metabolite H4 than clopidogrel.

Conclusion: AT-10 showed better inhibition of platelet aggregation in poor metabolizers as compared to Clopidogrel. AT-10 may emerge as a potential alternative to Clopidogrel as an anti-platelet drug. It can be further developed in clinical studies for the unmet medical needs in management of CVDs and overcome the pharmacogenomic limitations of Clopidogrel.

Trial Registration Number: Clinical Trial Registry-India URL: http://ctri.nic.in.

Registration Number: CTRI/2021/03/032206.

References

Yusuf S, Zhao F, Mehta S, Chrolavicius S, Tognoni G, Fox K . Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345(7):494-502. DOI: 10.1056/NEJMoa010746. View

Wallentin L, Becker R, Budaj A, Cannon C, Emanuelsson H, Held C . Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361(11):1045-57. DOI: 10.1056/NEJMoa0904327. View

Gurbel P, Bliden K, Hiatt B, OConnor C . Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003; 107(23):2908-13. DOI: 10.1161/01.CIR.0000072771.11429.83. View

Zhao X, Ma S, Kang Y, Tang C, Liu B, Jiang H . Antiplatelet effect, safety, and pharmacokinetics of vicagrel in patients with coronary artery disease undergoing percutaneous coronary intervention. Eur Heart J Cardiovasc Pharmacother. 2022; 8(8):806-814. DOI: 10.1093/ehjcvp/pvac026. View

Lindstrom M, DeCleene N, Dorsey H, Fuster V, Johnson C, LeGrand K . Global Burden of Cardiovascular Diseases and Risks Collaboration, 1990-2021. J Am Coll Cardiol. 2022; 80(25):2372-2425. DOI: 10.1016/j.jacc.2022.11.001. View

Matetzky S, Shenkman B, Guetta V, Shechter M, Beinart R, Bienart R . Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004; 109(25):3171-5. DOI: 10.1161/01.CIR.0000130846.46168.03. View

Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid N, Okazaki O . Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos. 2009; 38(1):92-9. DOI: 10.1124/dmd.109.029132. View

Menozzi A, Lina D, Conte G, Mantovani F, Ardissino D . Antiplatelet therapy in acute coronary syndromes. Expert Opin Pharmacother. 2011; 13(1):27-42. DOI: 10.1517/14656566.2012.642862. View

Virani S, Newby L, Arnold S, Bittner V, Brewer L, Demeter S . 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023; 148(9):e9-e119. DOI: 10.1161/CIR.0000000000001168. View

10.

Sangkuhl K, Klein T, Altman R . Clopidogrel pathway. Pharmacogenet Genomics. 2010; 20(7):463-5. PMC: 3086847. DOI: 10.1097/FPC.0b013e3283385420. View

11.

Shuldiner A, OConnell J, Bliden K, Gandhi A, Ryan K, Horenstein R . Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009; 302(8):849-57. PMC: 3641569. DOI: 10.1001/jama.2009.1232. View

12.

Shetkar S, Ramakrishnan S, Seth S, Chandna P, Verma S, Bhargava B . CYP 450 2C19 polymorphisms in Indian patients with coronary artery disease. Indian Heart J. 2014; 66(1):16-24. PMC: 3946470. DOI: 10.1016/j.ihj.2013.10.001. View

13.

Kontos M, Diercks D, Kirk J . Emergency department and office-based evaluation of patients with chest pain. Mayo Clin Proc. 2010; 85(3):284-99. PMC: 2843115. DOI: 10.4065/mcp.2009.0560. View

14.

Scott S, Sangkuhl K, Stein C, Hulot J, Mega J, Roden D . Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013; 94(3):317-23. PMC: 3748366. DOI: 10.1038/clpt.2013.105. View

15.

Adithan C, Gerard N, Vasu S, Rosemary J, Shashindran C, Krishnamoorthy R . Allele and genotype frequency of CYP2C19 in a Tamilian population. Br J Clin Pharmacol. 2003; 56(3):331-3. PMC: 1884356. DOI: 10.1046/j.1365-2125.2003.01883.x. View

16.

Lee S, Jeong Y, Hong D, Choi K, Lee J, Park T . Clinical Impact of CYP2C19 Genotype on Clopidogrel-Based Antiplatelet Therapy After Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2023; 16(7):829-843. DOI: 10.1016/j.jcin.2023.01.363. View

17.

Xiang Q, Pang X, Liu Z, Yang G, Tao W, Pei Q . Progress in the development of antiplatelet agents: Focus on the targeted molecular pathway from bench to clinic. Pharmacol Ther. 2019; 203:107393. DOI: 10.1016/j.pharmthera.2019.107393. View

18.

Mega J, Close S, Wiviott S, Shen L, Hockett R, Brandt J . Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2008; 360(4):354-62. DOI: 10.1056/NEJMoa0809171. View

19.

Byrne R, Rossello X, Coughlan J, Barbato E, Berry C, Chieffo A . 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023; 44(38):3720-3826. DOI: 10.1093/eurheartj/ehad191. View

20.

Gong I, Crown N, Suen C, Schwarz U, Dresser G, Knauer M . Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response. Eur Heart J. 2012; 33(22):2856-2464a. DOI: 10.1093/eurheartj/ehs042. View